Zhi Xu

机构：Cornell University, NYU Langone Health, Ultragenyx Pharmaceutical (United States), Jiangxi Applied Engineering Vocational Institute, Jersey Shore University Medical Center, Pingxiang University · ORCID：0000-0001-7228-408X

发表论文 76 篇 · 总被引 1980 次 · h-index 20

代表论文

• Isobavachalcone sensitizes cells to E2‐induced paclitaxel resistance by down‐regulating CD 44 expression in ER + breast cancer cells (2018 · Journal of Cellular and Molecular Medicine · 被引 27)
• Heat-induced manganese-doped magnetic nanocarriers combined with Yap-siRNA for MRI/NIR-guided mild photothermal and gene therapy of hepatocellular carcinoma (2021 · Chemical Engineering Journal · 被引 24)
• Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer‐related pathways in breast cancer (2019 · Cancer Medicine · 被引 22)
• Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non‐small cell lung cancer (2023 · Cancer Medicine · 被引 17)
• Additive manufacturing of degradable metallic scaffolds for material-structure-driven diabetic maxillofacial bone regeneration (2024 · Bioactive Materials · 被引 16)
• Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2 (2023 · Journal of Translational Medicine · 被引 16)